Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D H Boldt

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Investigational New Drugs|May 1, 1993
A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumorsD R Adkins, R Irvin, J Kuhn, et al.
Leukemia|October 1, 1994
Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reactionJ P Radich, K J Kopecky, D H Boldt, et al.
Leukemia|March 10, 2001
Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group StudyS H Petersdorf, K J Kopecky, D R Head, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanomaJ P Dutcher, S Creekmore, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1991
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanomaJ P Dutcher, E R Gaynor, D H Boldt, et al.
Cancer Research|August 1, 1988
Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humansD H Boldt, B J Mills, B T Gemlo, et al.
Anti-Cancer Drugs|April 1, 1995
Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic studyK A Havlin, J G Kuhn, J Koeller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Cancer Research|June 1, 1985
Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)T J Melink, D D Von Hoff, J G Kuhn, et al.
Journal of the National Cancer Institute|September 5, 1990
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinomaE R Gaynor, G R Weiss, K A Margolin, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Investigational New Drugs|May 1, 1993
A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumorsD R Adkins, R Irvin, J Kuhn, et al.
Leukemia|October 1, 1994
Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reactionJ P Radich, K J Kopecky, D H Boldt, et al.
Leukemia|March 10, 2001
Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group StudyS H Petersdorf, K J Kopecky, D R Head, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanomaJ P Dutcher, S Creekmore, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1991
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanomaJ P Dutcher, E R Gaynor, D H Boldt, et al.
Cancer Research|August 1, 1988
Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humansD H Boldt, B J Mills, B T Gemlo, et al.
Anti-Cancer Drugs|April 1, 1995
Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic studyK A Havlin, J G Kuhn, J Koeller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Cancer Research|June 1, 1985
Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)T J Melink, D D Von Hoff, J G Kuhn, et al.
Journal of the National Cancer Institute|September 5, 1990
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinomaE R Gaynor, G R Weiss, K A Margolin, et al.
Pageof 7